Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 2Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2Sarcoma 1Myeloid 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × ceralasertib × Thoracic × Clear all
NCT04550104 2025-12-19

CONCORDE

University of Leeds

Phase 1 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06754761 2025-01-01

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

AstraZeneca

Phase 1 Not yet recruiting
8 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡